BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...
BioCentury | May 23, 2020
Politics, Policy & Law

Delayed expectations for China’s patent reform

Four months after China signed a “Phase One” trade deal with the U.S., patent law amendments may not be among the priorities of the National People’s Congress, leaving it unclear when expected pharmaceutical patent protections...
BioCentury | Dec 9, 2019
Politics & Policy

Forward movement on drug pricing bill, enactment uncertain

Chairs of the Republican-controlled Senate Health Committee and the Democratic-controlled House Energy & Commerce Committee have agreed to support the Lower Health Care Costs Act of 2019 (S. 1895), giving the bill added momentum amid...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...with a market cap of nearly $4.8 billion. At the other end of the spectrum, Innovate Biopharmaceuticals Inc....
...NASDAQ:BIIB), Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Innovate Biopharmaceuticals Inc....
...Diego, Calif. Stephen Hansen Akcea Therapeutics Inc. Amarin Corp. plc AnaptysBio Inc. Ascletis Pharma Inc. BeiGene Ltd. BGI Genomics Co. Ltd. BioArctic AB Illumina Inc. Innovate Biopharmaceuticals Inc. Ionis...
BioCentury | Apr 6, 2018
Targets & Mechanisms

GI Band-Aid

...Genome plans to submit an IND for an IBD trial of SG-2-0776 early in 2019. Innovate Biopharmaceuticals Inc....
...Institutions Mentioned BiomX Ltd., Ness Ziona, Israel Broad Institute of MIT and Harvard, Cambridge, Mass. Innovate Biopharmaceuticals Inc....
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...the gainers collectively generated $6.9 billion in new market value. Autoimmune and inflammation drug developer Innovate Biopharmaceuticals Inc....
...Park, Calif. Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genmab A/S (CSE:GEN; Pink:GMXAY), Copenhagen, Denmark Innovate Biopharmaceuticals Inc....
...tesirine (SC16LD6.5) AbbVie Inc. Ablynx N.V. Atara Biotherapeutics Axovant Sciences Ltd. BGI Genomics Co. Ltd. Biogen Inc. Bristol-Myers Squibb Co. Dermira Inc. Exelixis Inc. Genmab A/S Innovate Biopharmaceuticals Inc. Johnson...
BioCentury | Nov 29, 2017
Emerging Company Profile

Gluten-free gut

...KumaMax could have safety advantages over therapies that target the body’s intestinal or immune cells. Innovate Biopharmaceuticals Inc.’s...
...Oaks, Calif. Celimmune LLC, Bethesda, Md. Immunogenics LLC, Newport Beach, Calif. ImmusanT Inc., Cambridge, Mass. Innovate Biopharmaceuticals Inc....
BioCentury | Jul 21, 2017
Strategy

Starting the conversation

Brent Saunders, Chairman, President & CEO of Allergan plc , brought the concept of a social contract to the forefront of discussions about drug companies in September 2016 with a blog post and company statement about...
BioCentury | Mar 7, 2016
Company News

Alba, Innovate Biopharmaceuticals deal

...financial terms, and Alba did not respond to inquiries. Alba Therapeutics Corp. , Baltimore, Md. Innovate Biopharmaceuticals Inc....
BioCentury | Oct 23, 2015
Company News

Valeant faces PhRMA attack, will discuss fraud allegation

PhRMA posted an Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), saying the company's "strategy is more reflective of a hedge fund than an innovative biopharmaceutical company." The article, by PhRMA SVP of Communications Robert Zirkelbach, contrasted...
Items per page:
1 - 10 of 17
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset

In recent years, it has become fashionable to focus on the high price of new treatments for certain cancers and rare diseases. Many observers ask why it is that U.S. citizens should subsidize the rest...
BioCentury | May 23, 2020
Politics, Policy & Law

Delayed expectations for China’s patent reform

Four months after China signed a “Phase One” trade deal with the U.S., patent law amendments may not be among the priorities of the National People’s Congress, leaving it unclear when expected pharmaceutical patent protections...
BioCentury | Dec 9, 2019
Politics & Policy

Forward movement on drug pricing bill, enactment uncertain

Chairs of the Republican-controlled Senate Health Committee and the Democratic-controlled House Energy & Commerce Committee have agreed to support the Lower Health Care Costs Act of 2019 (S. 1895), giving the bill added momentum amid...
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...with a market cap of nearly $4.8 billion. At the other end of the spectrum, Innovate Biopharmaceuticals Inc....
...NASDAQ:BIIB), Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Innovate Biopharmaceuticals Inc....
...Diego, Calif. Stephen Hansen Akcea Therapeutics Inc. Amarin Corp. plc AnaptysBio Inc. Ascletis Pharma Inc. BeiGene Ltd. BGI Genomics Co. Ltd. BioArctic AB Illumina Inc. Innovate Biopharmaceuticals Inc. Ionis...
BioCentury | Apr 6, 2018
Targets & Mechanisms

GI Band-Aid

...Genome plans to submit an IND for an IBD trial of SG-2-0776 early in 2019. Innovate Biopharmaceuticals Inc....
...Institutions Mentioned BiomX Ltd., Ness Ziona, Israel Broad Institute of MIT and Harvard, Cambridge, Mass. Innovate Biopharmaceuticals Inc....
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...the gainers collectively generated $6.9 billion in new market value. Autoimmune and inflammation drug developer Innovate Biopharmaceuticals Inc....
...Park, Calif. Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genmab A/S (CSE:GEN; Pink:GMXAY), Copenhagen, Denmark Innovate Biopharmaceuticals Inc....
...tesirine (SC16LD6.5) AbbVie Inc. Ablynx N.V. Atara Biotherapeutics Axovant Sciences Ltd. BGI Genomics Co. Ltd. Biogen Inc. Bristol-Myers Squibb Co. Dermira Inc. Exelixis Inc. Genmab A/S Innovate Biopharmaceuticals Inc. Johnson...
BioCentury | Nov 29, 2017
Emerging Company Profile

Gluten-free gut

...KumaMax could have safety advantages over therapies that target the body’s intestinal or immune cells. Innovate Biopharmaceuticals Inc.’s...
...Oaks, Calif. Celimmune LLC, Bethesda, Md. Immunogenics LLC, Newport Beach, Calif. ImmusanT Inc., Cambridge, Mass. Innovate Biopharmaceuticals Inc....
BioCentury | Jul 21, 2017
Strategy

Starting the conversation

Brent Saunders, Chairman, President & CEO of Allergan plc , brought the concept of a social contract to the forefront of discussions about drug companies in September 2016 with a blog post and company statement about...
BioCentury | Mar 7, 2016
Company News

Alba, Innovate Biopharmaceuticals deal

...financial terms, and Alba did not respond to inquiries. Alba Therapeutics Corp. , Baltimore, Md. Innovate Biopharmaceuticals Inc....
BioCentury | Oct 23, 2015
Company News

Valeant faces PhRMA attack, will discuss fraud allegation

PhRMA posted an Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX), saying the company's "strategy is more reflective of a hedge fund than an innovative biopharmaceutical company." The article, by PhRMA SVP of Communications Robert Zirkelbach, contrasted...
Items per page:
1 - 10 of 17